Number | Percent | |
---|---|---|
Men | 277 | (55.6) |
Age, mean (SD) | 68.6 | (14.2) |
Setting | ||
Short term inpatient unit | 386 | (76.6) |
Rehabilitation services or long term unit | 31 | (6.2) |
Outpatient clinic | 55 | (10.9) |
Medical consultation | 32 | (6.3) |
Service requesting consultation | (N = 493) a | |
Oncology | 141 | (28.6) |
Gastroenterology and hepatology | 119 | (24.1) |
Pneumology | 56 | (11.4) |
Geriatrics | 50 | (10.1) |
Internal Medecine | 36 | (7.3) |
Neurology | 17 | (3.4) |
Haematology | 15 | (3.0) |
Dermatology | 14 | (2.8) |
Radiotherapy | 7 | (1.4) |
Others | 17 | (14.0) |
Cancer history | ||
Incurable at the initial diagnosis (N = 371) a | 217 | (58.5) |
Metastatic sites | (N = 393) a | |
0 | 45 | (11.5) |
1 | 104 | (26.5) |
2 | 115 | (29.3) |
3 or more | 129 | (32.8) |
Current evolution of disease | (N = 456) a | |
At diagnosis (treatment not started) | 47 | (10.3) |
Stability or answer to treatment | 35 | (7.6) |
Progression (local or metastatic) | 374 | (82.0) |
Antitumoral treatment was : | (N = 433) a | |
Not yet or never started | 108 | (24.9) |
Continuing | 166 | (38.3 |
Discontinued | 159 | (36.7) |
Prognostic factors | ||
PSb ≥ 3 and/or Karnofski ≤ 50 (n = 474) | 336 | (70.9) |
Albumin, g/L, median (Q1-Q3) (n = 246) | 29 | (23–33) |